Launch of Six New Research Innovation Products Demonstrates Phapros' Commitment to Business Growth

JAKARTA, June 13, 2024 – Throughout 2024, PT Phapros Tbk has various strategic initiatives to drive its business growth. As part of the state-owned pharmaceutical holding, the company is committed to introducing several new products that will serve as growth engines for the corporation. Speaking on a different occasion, Acting President Director of PT Phapros Tbk, Ida Rahmi Kurniasih, stated that this year Phapros will have six new product registration numbers, all of which are internally developed by the Phapros R&D Team.

Four of the six new products will be aimed at preventive and promotive therapies for children.

"We are currently developing children's products with more advanced drug formulation technology. The dosage forms we will launch are like gummy candies and lozenges, making them more appealing to children," she said during an interview in Jakarta (13/6).

Ida acknowledged that Phapros is now focusing on children's health, considering that Indonesia is experiencing a demographic bonus, with a significant portion of the population being of productive age (15 to 64 years) by 2045. Therefore, children's growth and health need to be supported so that by 2045, they can become an excellent generation to lead the nation.

In line with Phapros' program, the Ministry of Health of the Republic of Indonesia is also prioritizing basic (primary) health services by promoting preventive efforts, and the use of technology in five priorities: improving maternal and child health, accelerating community nutrition improvement, controlling diseases such as HIV, malaria, and tuberculosis, fostering healthy community movements, and strengthening health facilities.

"In addition to the four new products related to the children's segment, two other products are therapeutic agents for tuberculosis and injectable antibiotics. We are optimistic that these six products will be catalysts for Phapros' business growth in the future, along with the existing products," Ida added.

The National Socioeconomic Survey (Susenas) by the Central Bureau of Statistics (BPS) estimated that the early childhood population (0-6 years) in Indonesia reached 30.2 million as of March 2023. This figure represents 10.91% of the total population of Indonesia. Meanwhile, tuberculosis cases in Indonesia, according to data from the Ministry of Health, showed an increase in 2023, with 820,789 cases found out of an estimated 1,060,000 cases.

"This means that the market for children's medicine in Indonesia is quite large, including for TB patients. This is where Phapros plays a role," she concluded.